On March 04, Cross Country Healthcare, Inc. (NASDAQ:CCRN) announced financial results for the fourth quarter and full year ended December 31, 2014. Revenue was $188.1 million, up 72% year-over-year and 8% on a pro forma basis. Adjusted EBITDA was $6.2 million or 3.3% of revenue. On Tuesday shares of Cross Country Healthcare, Inc. (NASDAQ:CCRN) closed at $10.93. Company’s sales growth for last 5 years was -7.10% and EPS growth for next 5 years is recorded as 25.00%.
On March 3, Goodwill Industries International and Bon-Ton Stores Inc. (NASDAQ:BONT) encourage people to clean out their closets and make a fresh start this spring. Donors can set aside clothing and household textiles such as apparel, outerwear, shoes, handbags, blankets or comforters they no longer need and donate them to Goodwill during the Bon-Ton Goodwill Sale from March 12 – 28. Bon-Ton Stores Inc. (NASDAQ:BONT) in last trading activity increased 7.39% to close at $4.94. Company weekly performance is -7.32% while its quarterly performance stands at -28.09%. Bon-Ton Stores Inc. (NASDAQ:BONT) is -58.20% away from its 52 week high.
On March 4, Onconova Therapeutics, Inc. (NASDAQ:ONTX) announced that Ajay Bansal, Chief Financial Officer, will present at the 27th Annual ROTH Conference in Laguna Niguel, CA. The presentation will take place on Wednesday, March 11th at 11:00 a.m. PT. On last trading day Onconova Therapeutics, Inc. (NASDAQ:ONTX) fell -1.29% to close at $2.29. Its volatility for the week is 4.29% while volatility for the month is 4.42%. Onconova Therapeutics, Inc. (NASDAQ:ONTX) monthly performance is -7.66%.
Linear Technology (NASDAQ:LLTC) has earned an “A+” credit rating from analysts at Morningstar. The firm’s “A+” rating suggests that the company is a low default risk. They also gave their stock a three star rating. Linear Technology Corporation (NASDAQ:LLTC) has 0.80% insider ownership while its institutional ownership stands at 92.30%. In last trading activity company’s stock closed at $46.86.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) canceled two investor meetings, sparking speculation that a deal to buy the drugmaker could be in the works. Acadia had been scheduled to speak at a March 3 conference hosted by Cowen & Co. and a conference Tuesday hosted by Roth Capital Partners. On last trading day ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) increased 17.85% to close at $45.88. Its volatility for the week is 6.82% while volatility for the month is 4.13%. ACAD’s sales growth for past 5 years was -56.50% and its EPS growth for past 5 years was 4.60%. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) monthly performance is 41.26%.